A study led by the Institute of Bioengineering of Catalonia (IBEC) describes the development of an organ-on-a-chip that mimics the human blood-brain barrier. With this system, researchers can study th...
Read moreD-Sight ha recibido un millón de euros de inversión por parte del fondo de capital riesgo Clave Capital para desarrollar nuevas estrategias terapéuticas innovadoras para el tratamiento de la retino...
Read moreEsta inversión marca el inicio de una nueva etapa para la compañía, con nuevos retos y desafíos, y acompaña en el camino para conseguir el objetivo; mejorar el diagnóstico en ginecología convir...
Read moreConnecta Therapeutics, a clinical stage biotechnology company focusing on the development of new treatments for central nervous system (CNS) disorders without therapeutic options, has been granted ...
Read moreGENESIS Tech Transfer Boost, an investment vehicle created in 2022 and managed by the consultancy firm GENESIS Biomed, has made its first investment for a ticket of €25,000 in the biotech company Sp...
Read moreLa financiación levantada por las empresas que forman parte de la Comunidad PCB, en operaciones identificadas en el ejercicio 2022, alcanzó los 142M€, un récord absoluto, de los que 83M€ (un 58...
Read moreNuage Therapeutics (“Nuage”) announces today the successful closing of a €12 million Seed financing to support the development of its lead program and validate its pioneering drug discovery plat...
Read moreOneChain Immunotherapeutics (OCI), a clinical stage biotech company focused on the development of CAR-T candidates for the treatment of oncological diseases, today announced the closing of a €6.7 mi...
Read moreOrikine Bio, a biotech company developing a novel proprietary platform for cytokine-based therapies for autoimmune and inflammatory diseases, announces today the successful closing of a €5.5m seed f...
Read moreAsabys has announced that the Institut Català de Finances (ICF) has joined its new venture capital fund, Sabadell Asabys Health Innovation Investments II (Sabadell Asabys II), with 10 million euros. ...
Read moreADmit Therapeutics is a biotechnology company founded at the end of 2017 as a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL). The company is focused on the development and commerc...
Read moreLa empresa, dirigida por el doctor Pablo Escribá, ha desarrollado Lam561, un fármaco específico para combatir el glioblastoma y prolongar la esperanza de vida de los pacientes afectados por este ti...
Read more